Edison Issues ADR Update on Bavarian Nordic

18 Feb, 2016, 12:06 ET from Edison Investment Research

LONDON, February 18, 2016 /PRNewswire/ --

Bavarian Nordic's intention to list on NASDAQ is a strategic move to broaden its appeal to US investors and raise additional funds to accelerate clinical development of multi-tumor cancer immunotherapy CV-301 and respiratory syncytial virus vaccine MVA-BN RSV and to expand its manufacturing capacity. As a well-funded revenue generating company, it should still appeal to investors despite market headwinds. While pricing is to be determined, the likely timing of the proposed IPO represents an attractive entry point for US investors ahead of a newsflow-rich 2016.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Our updated valuation is $1,819m or $21.6/ADR (down from $1,842m or $66.2/ADR) on account of rolling forward in time, updating net cash and DKK/US$ strengthening. A successful IPO would provide greater clarity on MVA-BN RSV and CV-301 development plans/timelines, representing upside potential. RSV is a significant opportunity; although, in the absence of clinical data we do not yet include a contribution for MVA-BN RSV. More insight into the clinical program for MVA-BN Brachyury (also not yet included in our valuation) and additional income from J&J for MVA-BN Filovirus and MVA-BN HPV also represent upside.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website: http://www.edisoninvestmentresearch.com.

About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

 

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  
LinkedIn    http://www.linkedin.com/company/edison-investment-research
Twitter    http://www.twitter.com/Edison_Inv_Res
YouTube    http://www.youtube.com/edisonitv
Google+    https://plus.google.com/105425025202328783163/posts

For more information please contact:
Lala Gregorek, Edison Investment Research, +44-(0)20-3681-2527
Christian Glennie, Edison Investment Research, +44-(0)20-3077-5727
healthcare@edisongroup.com

SOURCE Edison Investment Research